Actively Recruiting
Phase III Study of ZG006 for Safety, Tolerability, and Effectiveness in Adults With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma
Led by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Updated on 2024-12-16
78
Participants Needed
1
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a multicenter, open-label phase III trial to study ZG006 in patients with advanced small cell lung cancer or neuroendocrine carcinoma. The study aims to assess the safety, tolerability, and effectiveness of ZG006, a biological drug given by intravenous infusion. It focuses on patients with these advanced cancers and evaluates how well the drug works and how safe it is for them. The study has two parts. Part 1 involves increasing doses of ZG006 starting from 0.1 mg up to 3 mg to find the safest and most effective dose. After this, investigators will decide on two recommended doses to use in Part 2. In Part 2, the selected doses will be given to patients with neuroendocrine carcinoma to further evaluate safety and efficacy. Participants receive the treatment through IV infusion during both parts of the study. Participants will be monitored for response to treatment for up to two years, with the main measure being the objective response rate. Safety will also be tracked by recording any adverse events during the same period. The trial involves regular assessments including physical exams and performance status evaluations to understand how participants respond to ZG006. The total participation duration varies but includes close follow-up to monitor treatment effects and side effects.
CONDITIONS
Brief Title
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
Research Team
S
Shangdi Ning
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here